why choose us

First received: September 05, 2023

Clinical Trial: Xeomin vs Botox for Treatment of Overactive Bladder Syndrome

Study Status: Completed

Recruit Status: RECRUITING

Condition: Overactive Bladder Syndrome

Study Type: INTERVENTIONAL


Official Title: IncobotulinumtoxinA (Xeomin®) vs OnabotulimuntoxinA (Botox®) for Treatment of Overactive Bladder Syndrome: Randomized Non-Inferiority Trial

Brief Summary: Purpose: Multiple formulations and brands of botulinum toxin exist on the market today.Only OnabotulinumtoxinA (BOTOX®) is currently FDA approved for treatment of overactive bladder.IncobotulinumtoxinA (XEOMIN®) is a similar formulation of botulinum toxin A that has similar dosing and safety profile at onabotulinumtoxinA.OnabotulinumtoxinA is the most expensive formulation on the market.Compare the efficacy of incobotulinumtoxinA (Xeomin®, Merz Pharmaceuticals) to onabotulinumtoxinA (Botox®, Allergan) for…

Read more